AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Teladoc Health Q2 Earnings Beat Estimates with $631.9M Revenue and -$0.19 EPS
ByAinvest
Tuesday, Jul 29, 2025 4:11 pm ET1min read
Teladoc Health reported Q2 GAAP EPS of -$0.19, beating expectations by $0.07. Revenue of $631.9M (-1.6% Y/Y) also beat expectations by $9.1M. Q3 and FY25 revenue and EPS consensus estimates were $628.49M and -$0.24, and $2.52B and -$1.16, respectively.
Teladoc Health Inc. (NYSE: TDOC) reported its Q2 2025 financial results, with GAAP EPS of -$0.19, beating expectations by $0.07. Revenue of $631.9M (-1.6% Y/Y) also exceeded estimates by $9.1M. The company's 3Q25 revenue and EPS consensus estimates were $628.49M and -$0.24, respectively, while the full-year 2025 revenue and EPS consensus estimates were $2.52B and -$1.16, respectively [1].The company expects 3Q2025 revenue to range between $614 million and $636 million, with adjusted EBITDA expected to be between $56 million and $70 million. The net loss per share is forecasted to be between $0.35 and $0.20. For the full year of 2025, Teladoc Health expects revenue to be between $2.51 billion and $2.548 billion, with adjusted EBITDA expected to be between $263 million and $294 million. The net loss per share is projected to be between $1.35 and $1.00, while free cash flow is expected to be between $170 million and $200 million [1].
Teladoc Health's stock performance on July 30, 2025, saw a slight decrease, with the stock trading at $7.80, down from the previous close of $8.20. The stock has seen significant volatility, with a 52-week low of $6.35 and a 52-week high of $15.21. Over the past year, the stock has returned -14.42% compared to the sector index, which has returned -9.8% [2].
Analysts have a mixed view on Teladoc Health, with 31% recommending a buy, 68% holding, and 0% selling. The average target price is $9.16, representing an upside of 17.47% compared to the current price of $7.80. The stock's market capitalization is $1.4 billion, with a P/E ratio of 8.14 and a profit margin of -39.66% [2].
References:
[1] https://seekingalpha.com/news/4473770-teladoc-health-gaap-eps-of-0_19-beats-by-0_07-revenue-of-631_9m-beats-by-9_1m
[2] https://www.indmoney.com/us-stocks/teladoc-inc-share-price-tdoc
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet